Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases.
about
Interleukin-6 blockade in ocular inflammatory diseasesPotential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical reviewIL-6 receptor α defines effector memory CD8+ T cells producing Th2 cytokines and expanding in asthmaAdipocyte activation of cancer stem cell signaling in breast cancerCombining somatic mutations present in different in vivo affinity-matured antibodies isolated from immunized Lama glama yields ultra-potent antibody therapeutics.Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Biologic Therapy for the Treatment of Giant Cell Arteritis.Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options.Treatment of adult-onset still's disease: up to date.An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo.Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma.Treat-to-target in systemic lupus erythematosus: are we there yet?Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension.Current and emerging therapies in large-vessel vasculitis.Multifaceted Roles of Interleukin-6 in Adipocyte-Breast Cancer Cell Interaction.Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial.
P2860
Q27011357-F4DF33A3-2289-4706-9F73-EF2397495EFAQ27024465-9CB28A13-B512-481F-9F93-8F49B2FDAABDQ34987183-33E7B291-CFEE-4742-A691-C8C8D104C336Q35622172-91F0581F-C013-4239-BFD2-013912DD2A86Q35946548-E0C9EA34-DABF-4B03-BC1B-20601BE01DF7Q36484383-967DB197-827E-49AE-94FD-E3135AD439DDQ37439687-B9BE8A0C-4536-4982-91DA-36EAAAEC4E56Q37498527-6BB26A85-C3A3-4181-8AA2-541068A86FC0Q38189135-E59F6F52-E87E-4EB9-91F4-E052CA83F930Q38264622-64677A10-A71A-4E1F-B6F9-21FFD022719CQ38329024-21E7F04F-BCF7-456A-A8B6-3196BFA4EE68Q38679486-B12BF5CC-5598-4F18-B31E-2658898D94D5Q38931171-E74F8B60-A4F0-40C1-A43B-80877A8F64A3Q42251072-61DE521D-4682-499B-9707-9141FFA7687EQ47846085-E4B15E88-67B7-4337-8071-72C1A6A573B5Q47909446-FCFA183E-0589-4D4A-B97F-4ACF038F21ACQ50082820-94F8FF0D-F83C-4F68-ABF9-0C391D3A30E6Q50137412-584B2552-51AB-4B2E-92B6-B059165E92BAQ50700806-1ED546BE-2EDD-47FB-8349-F387F360D4E5
P2860
Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tocilizumab: a novel humanized ...... flammatory rheumatic diseases.
@en
type
label
Tocilizumab: a novel humanized ...... flammatory rheumatic diseases.
@en
prefLabel
Tocilizumab: a novel humanized ...... flammatory rheumatic diseases.
@en
P2860
P1433
P1476
Tocilizumab: a novel humanized ...... flammatory rheumatic diseases.
@en
P2093
Rieke Alten
Tazio Maleitzke
P2860
P304
P356
10.3109/07853890.2013.771986
P407
P577
2013-05-08T00:00:00Z